refractory cancer

A malignancy for which surgery is ineffective, which is either initially unresponsive to chemo- or radiation therapy, or which becomes unresponsive over time

refractory cancer

Oncology Cancer that is unresponsive to treatment. See Radioinsensitive.
Mentioned in ?
References in periodicals archive ?
Coverage includes the need for a specialized interest combining palliative care and nutrition; general concepts; personal perspectives; quality of life in the young and adults; the world's major religions' views on end-of-life issues; Japanese, Chinese, and Indian perspectives; forgoing of tube feeding; artificial nutrition; gastrointestinal side effects and symptoms; gastrojejunostomy; withholding or withdrawing nutritional support; vitamin deficiency; hydration; dysphasia; appetite loss; fatigue; taste and smell alterations; nausea; refractory cancer cachexia; head and neck cancer; the vegetative state; renal failure; end-stage liver disease; motor disease; effects of steroids; and appetite stimulants.
The Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial randomly assigned a total of 950 men with advanced prostate cancer in a 2:1 fashion to satraplatin (80 mg/[m.
A novel pain drug from puffer fish poison showed an analgesic effect that lasted up to 2 weeks following intramuscular injection in patients with refractory cancer pain, Dr.
Alain Moussy, CEO of AB Science, said "The acceptance of this Marketing Authorization Application by EMA shows that authorities consider masitinib as a potential candidate for registration in this refractory cancer, despite the small size of the phase 2 study.
Refractory cancer occurs when a patient's disease is resistant to treatment or in the case of multiple myeloma, the disease progresses within 60 days of their last therapy.
gov Identifier: NCT01813539) consists of a dose-escalation phase followed by an adaptive safety study conducted in patients with advanced, refractory cancer.
Neville, the Experimental Therapeutics in Pediatric Cancer Program is quickly gaining recognition as a regional referral center, giving children with recurrent or refractory cancer a local option to pursue experimental treatment with early-phase anti-cancer drugs.
Patient enrollment is completed for the Phase 3 Satraplatin and Prednisone Against Refractory Cancer (SPARC) registrational trial, which is assessing the safety and efficacy of satraplatin in combination with prednisone as a second-line chemotherapy in patients with HRPC.
Proxinium(TM) Achieves 25% Complete Response Rate in Highly Refractory Cancer
Satraplatin in patients with advanced hormone-refractory prostate cancer: Overall survival results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial," (Abstract #5003), Presenter: A.
Advanced refractory cancer patients treated in a previous clinical study at MD Anderson Cancer Center in Texas had longer than expected survival times.
The Phase I clinical study is designed to evaluate the safety and pharmacokinetic profile of LP-261 in patients with advanced metastatic tumors or blood cancers, as well as refractory cancer that has progressed despite previous chemotherapy.